Literature DB >> 12911173

Successful management of acute renal artery thromboembolism by intra-arterial thrombolytic therapy with recombinant tissue plasminogen activator.

Ben-Chung Cheng1, Sheung-Fat Ko, Feng-Rong Chuang, Chih-Hsiung Lee, Jin-Bor Chen, Kuo-Tai Hsu.   

Abstract

Acute renal artery thromboembolism (ARAT), a rare event in native kidneys, potentially result in severe renal injury if it is not appropriately managed. The optimal therapy still remains controversial today even though various methods of managements for ARTA were applied in these decades including surgical intervention and medical approach such as thrombolytic therapy. Recombinant tissue plasminogen activator (rt-PA) reveals a better bioavailability and lower incidence of adverse effects and it has been widely used to treat a number of clinical conditions but only very few cases have been reported where rt-PA was used to treat ARAT. We described a case of ARAT, which was successfully treated by the administration of rt-PA via intra-arterial infusion within a period of 60 min without residual renal impairment. It may be a useful choice for ARAT and renal infarction sufferers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12911173     DOI: 10.1081/jdi-120022560

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  2 in total

1.  Acute renal infarction presenting with acute abdominal pain secondary to newly discovered atrial fibrillation: a case report and literature review.

Authors:  Sherif Ali Eltawansy; Shil Patel; Mana Rao; Samaa Hassanien; Mihir Maniar
Journal:  Case Rep Emerg Med       Date:  2014-12-29

2.  Renal arteriography with endovascular ultrasound for the management of renal infarction patients.

Authors:  Fabrice Ivanes; Jean Dewaele; Caroline Touboul; Philippe Gatault; Bénédicte Sautenet; Christelle Barbet; Matthias Büchler; Laurent Quilliet; Denis Angoulvant; Jean-Michel Halimi
Journal:  BMC Nephrol       Date:  2020-07-14       Impact factor: 2.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.